Skip to main content

Keytruda

Pronunciation: key-true-duh
Generic name: pembrolizumab
Dosage form: solution for intravenous infusion
Drug class: Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 14, 2025.

What is Keytruda?

Keytruda (pembrolizumab) is an immunotherapy medication that treats multiple types of cancer by enhancing the body's natural immune response against cancer cells. First approved by the FDA in 2014, this treatment plays an important role in modern cancer therapy.

Keytruda is given as an infusion into your vein (IV infusion) every 3 to 6 weeks depending on the type of cancer you have. It can be used alone or with other medicines, including chemotherapy.

How does Keytruda work?

Keytruda works through a sophisticated mechanism called immune checkpoint inhibition:

Keytruda belongs to the drug class called immune checkpoint inhibitors and may also be called a monoclonal antibody.

Clinical trials have shown most people respond to Keytruda within 2-4 months of starting treatment (see How long does it take for Keytruda to work?).

Types of cancer treated with Keytruda

Keytruda is FDA-approved to treat numerous cancers, including certain types of:

Some cancers may need to be tested for genetic markers such as PD-L1, dMMR, TMB, or pMMR to determine if Keytruda is right for you.

Note that this is just a summary, see the Keytruda Prescribing Information for specific criteria and prior treatment requirements that may apply for each indication. 

Keytruda side effects

The most common side effects of Keytruda when it is used alone are:

Clinical trials have reported Keytruda side effects that are more common in children than adults are:

The most common side effects of Keytruda when it is used in combination with chemotherapy or radiotherapy treatments include:

Prompt medical attention to these side effects is crucial. Your doctor will monitor you during Keytruda treatment. 

Serious side effects and warnings

Keytruda is a medicine that works with your immune system to treat certain cancers. Keytruda can cause your immune system to attack normal organs and tissues in any area of your body and can cause serious side effects.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

For people who have had an organ transplant, Keytruda may cause rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had.

Complications, including graft-versus-host-disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death.

Get emergency medical help if you have signs of an allergic reaction to Keytruda (hives, difficulty breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Keytruda may cause harm to an unborn baby. Females of reproductive potential should use effective contraception.

Getting medical treatment right away for these side effects may help keep these problems from becoming more serious. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before taking this medicine

To make sure Keytruda is safe for you, tell your doctor if you have:

Pregnancy

Keytruda may harm an unborn baby. Your healthcare provider will give you a pregnancy test to make sure you are not pregnant. Use effective birth control while using Keytruda and for at least 4 months after your last dose. Tell your healthcare provider right away if you think you may be pregnant or if you become pregnant during
treatment with Keytruda.

Breastfeeding

It is not known if Keytruda passes into breast milk. Do not breastfeed while using this medicine and for at least 4 months after your last dose.

How is Keytruda administered?

Keytruda is administered as an infusion into your vein through an intravenous line over 30 minutes.

You will need frequent medical tests to help your doctor determine if you are tolerating Keytruda. Do not miss any follow-up visits.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your Keytruda infusion.

What happens if I overdose?

In a medical setting, an overdose would be treated quickly.

What should I avoid while receiving Keytruda?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What other drugs will affect Keytruda?

Other drugs may interact with your Keytruda infusion, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Check for Keytruda interactions here.

Does Keytruda interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Keytruda ingredients

Active ingredient: pembrolizumab
Inactive ingredients: L-histidine, polysorbate 80, sucrose, and water for injection

Who makes Keytruda?

Keytruda is manufactured by Merck & Co. (known as MSD outside the United States and Canada), and their global headquarters are located in Rahway, New Jersey, USA. Keytruda is Merck's top-selling product, generating over $20 billion in annual sales. Other notable medications by Merck include:

Keytruda Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Keytruda.

Keytruda (pembrolizumab) - Merck Sharp & Dohme LLC
Formulation type Strength
Single-Dose Vial 100 mg/4 mL (25 mg/mL)
Single-Dose Vial 50 mg Discontinued

Popular FAQ

What is the success rate of Keytruda?

In general, PD-1 immune checkpoint inhibitors like Keytruda have been shown to significantly prolong overall survival (OS) in some patients with various cancer types, but Keytruda does not always work for everyone. Continue reading

How long does it take for Keytruda to work?

The time it takes for Keytruda to work can vary based on the type and stage of cancer. Typically, a response to treatment becomes apparent within 2-4 months of starting Keytruda. This timeframe is referred to as "time to response," which measures when a patient's cancer begins to show signs of responding to the treatment. You can find the specific "time to response" data from clinical trials in the table below. Continue reading

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

What is the difference between Opdivo and Keytruda?

Opdivo (nivolumab) and Keytruda (pembrolizumab) are two immunotherapy drugs for various cancers. Both are monoclonal antibodies, known as PD1 inhibitors, first approved in 2014. Opdivo is from Bristol Myers Squibb, and Keytruda is from Merck & Co. The main differences lie in dosing, combination therapies, and approved cancer types. Continue reading

Pembrolizumab vs. nivolumab: How do they compare?

Pembrolizumab and nivolumab are both prescription medications used to treat various types of cancers, including solid tumors and blood cancers. They may be used alone or in combination with other medicines for cancers that are more advanced, have spread in the body, or are no longer responding to previous treatments. Continue reading

Can you take prednisone with Keytruda?

You should only use prednisone with Keytruda if your doctor has specifically prescribed these medicines for you. Prednisone is in a class of drugs known as corticosteroids. Prednisone may be used to treat serious or life-threatening immune-mediated side effects that may occur due to Keytruda treatment. Continue reading

Is Keytruda covered by Medicare / Medicaid?

Keytruda is usually covered by Medicare or Medicaid, but your costs can vary depending upon your plan coverage. For example, with a Medicare Advantage plan, 41% of patients had no out-of-pocket costs for the 200 mg dose of Keytruda. Most patients with Medicaid typically pay from $4 to $8 per Keytruda infusion. Your costs may be different based on your overall income, deductible or health plan. Continue reading

How are Inlyta and Keytruda used in kidney cancer?

Inlyta and Keytruda are given as a combination therapy for first-line treatment of kidney cancer (advanced renal cell carcinoma) in adults. Inlyta is an oral medication given 2 times per day and Keytruda is an intravenous (IV) infusion given every 3 weeks or every 6 weeks. Continue reading

How is pembrolizumab (Keytruda) administered?

Pembrolizumab (brand name: Keytruda) is a cancer medicine given into your vein as a slow intravenous (IV) infusion that usually takes about 30 minutes. You will most likely receive this treatment in an outpatient clinic or hospital setting every 3 or 6 weeks. Continue reading

View more FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.